Research Studies
Interested in participating in a clinical research trial?
Apply here and we will contact you within two business days!
Select your language
Selecciona tu idioma
What are clinical studies?
Why participate in a clinical study?
Are clinical studies dangerous?
Pediatric Monovalent COVID-19 Vaccine
Adults with Type 2 Diabetes
Crohn’s Disease/ Enfermedad de Crohn
Migraines in kids
Dry Age-Related Macular Degeneration (Dry AMD)
High Cardiovascular Risk
Overweight/Obese Adults without Diabetes
Pneumococcal Vaccine in Toddlers 12 – 15 Months of Age
Severe Asthma in Children/Adolescents
Ulcerative Colitis/Colitis Ulcerativa
Wet Age-Related Macular Degeneration (Wet AMD)
Monovalent COVID-19 Vaccine in Children
Monovalent (Omicron) COVID-19 Vaccine in Children
With the constant changes to the COVID-19 pandemic, we all want to give our kids the best protection. This study is evaluating a Monovalent COVID-19 Vaccine for children under 12 years old. This means that it has the potential to better protect against COVID variants this season. This dose and vaccine have already been proven safe and effective. The plan is to turn the COVID-19 vaccine into a one dose only vaccine.
If your child is between 5 years and 12 years old, and has not received any COVID-19 vaccine, please consider this option as it would be only one dose.
Participants will receive study treatment and procedures at no cost and will be eligible for reimbursement related to travel expenses and time.
Call Us
Can we call you
Pneumococcal Conjugate Vaccine in Healthy Toddlers 12 – 15 Months of Age
Pneumococcal Vaccine (PG4) for Children Aged 12 to 15 Months
Protecting our children from serious illnesses is a top priority. This clinical study is evaluating PG4 Pneumococcal Conjugate Vaccine for children between 12 and 15 months of age. Pneumococcal disease can cause severe infections such as pneumonia, meningitis, and bloodstream infections in young children.
PG4 has proven to be both safe and effective, offering protection against 25 strains of pneumococcus, compared to the previous vaccine, which protects against fewer strains. This vaccine acts as a booster, providing additional protection against the most common strains and helping to maintain long-term immunity.
If your child is between 12 and 15 months old and has not yet received a pneumococcal vaccine, they may be eligible to participate in this study.
All study-related vaccines and procedures will be provided at no cost, and families may be eligible for reimbursement for travel and time.
Call Us
Can we call you?
Study for Children and Adolescents with Severe Asthma
Study Summary
|
This study was designed to evaluate the efficacy of a new investigational rescue inhaler device for children and adolescents (ages 4-17) with severe asthma. This dry powder inhaler features both a broncodilator (albuterol sulfate) + corticosteroid, and will be compared to a typical rescue inhaler which only contains the broncodilator. There will be no cost to any participants in the trial. No medical insurance is required, legal status will not be asked for, and compensation may be provided |
Inclusion Criteria
|
Call Us